Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study

BACKGROUND: More than two years into the COVID-19 pandemic, most of the population has developed anti-SARS-CoV-2 antibodies from infection and/or vaccination. However, public health decision-making is hindered by the lack of up-to-date and precise characterization of the immune landscape in the popu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaballa, María-Eugenia, Perez-Saez, Javier, de Mestral, Carlos, Pullen, Nick, Lamour, Julien, Turelli, Priscilla, Raclot, Charlène, Baysson, Hélène, Pennacchio, Francesco, Villers, Jennifer, Duc, Julien, Richard, Viviane, Dumont, Roxane, Semaani, Claire, Loizeau, Andrea Jutta, Graindorge, Clément, Lorthe, Elsa, Balavoine, Jean-François, Pittet, Didier, Schibler, Manuel, Vuilleumier, Nicolas, Chappuis, François, Kherad, Omar, Azman, Andrew S., Posfay-Barbe, Klara M., Kaiser, Laurent, Trono, Didier, Stringhini, Silvia, Guessous, Idris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714630/
https://www.ncbi.nlm.nih.gov/pubmed/36474728
http://dx.doi.org/10.1016/j.lanepe.2022.100547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714630/
https://www.ncbi.nlm.nih.gov/pubmed/36474728
http://dx.doi.org/10.1016/j.lanepe.2022.100547

Ejemplares similares